• Fractyl Health set a Sept. 1, 2026 virtual Commercial Strategy Day outlining a proposed go-to-market plan for Revita, a one-time post-GLP-1 therapy.
• One-year randomized study results were already presented, showing Revita supported weight maintenance versus a sham procedure in a targeted patient group.
• Management will frame Revita as a procedural “off-ramp” for patients discontinuing GLP-1 drugs, addressing a large US treated population.
• Focus shifts to a six-month topline readout from the REMAIN-1 Pivotal Cohort expected in early Q4 2026.
• Regulatory plans include a potential FDA De Novo marketing application submission anticipated in late Q4 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fractyl Health Inc. published the original content used to generate this news brief on August 20, 2026, and is solely responsible for the information contained therein.